Quarterly Activities Report and 4C Quarterly Cash Flow Report – quarter ended 31 March 2024

ASX Announcements

Patrys has today released its Quarterly Activities Report and Appendix 4C Quarterly Cash Flow report for the quarter ended 31 March 2024.

Key highlights from this period include:

  • GMP production run initiated during the quarter, and successfully completed in April with product characterisation and quality verification on track for completion in Q2 CY2024;
  • Positive preclinical data highlights the potential to use deoxymabs to treat vasculitis, and potentially other autoimmune diseases, presented at international workshop;
  • Cash and short-term investment balance of $3 million on 31 March 2024.

Patrys  Chief  Executive  Officer  and  Managing  Director,  Dr. James  Campbell said:

“The  GMP manufacturing run for PAT-DX1 started during the quarter and subsequent to the end of the quarter has   recently   been   successfully   completed.   The   Company   expects   the   additional   product characterisation and specification testing will be completed by Q2 CY2024. We were also pleased to  announce that  after  the  end  of  the  quarter  positive  preclinical  data  concerning  deoxymabs  in animal models of the autoimmune disease vasculitis was  presented during the plenary session at a leading  international  workshop.  This  potentially  opens  up  a  new  therapeutic  area  for  Patrys  to develop or partner its deoxymab technology.” 

Read today’s ASX release here.